Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Repligen Corporation (RGEN)

176.94 -11.70 (-6.20%)
At close: October 30 at 4:00:01 PM EDT
176.94 0.00 (0.00%)
After hours: October 30 at 4:30:17 PM EDT
Trade RGEN on Coinbase
Chart Range Bar
Loading chart for RGEN
  • Previous Close 188.64
  • Open 175.37
  • Bid 163.78 x 200
  • Ask 186.99 x 200
  • Day's Range 171.23 - 180.30
  • 52 Week Range 100.99 - 198.87
  • Volume 4,472,060
  • Avg. Volume 1,178,172
  • Market Cap (intraday) 11.234B
  • Beta (5Y Monthly) 1.08
  • PE Ratio (TTM) --
  • EPS (TTM) -0.21
  • Earnings Date Oct 27, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 202.22
  • Morningstar Rating Rating available with Stock Picks access

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

www.repligen.com

2,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RGEN
7.98%
S&P 500 (^GSPC)
10.73%

1-Year Return

RGEN
22.39%
S&P 500 (^GSPC)
11.11%

3-Year Return

RGEN
54.98%
S&P 500 (^GSPC)
81.91%

5-Year Return

RGEN
39.09%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 209.31M
Earnings -38.43M
Profit Margin -18.36%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
50M
100M
150M
200M
-15.0%
-10.0%
-5.0%
0.0%
5.0%

Analyst Insights

View More

Analyst Price Targets

175.00
202.22 Average
176.94 Current
235.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/28/2026
Analyst RBC Capital
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 185 -> 200

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -1.47%

  • Return on Assets (ttm)

    1.40%

  • Return on Equity (ttm)

    -0.57%

  • Revenue (ttm)

    805.61M

  • Net Income Avi to Common (ttm)

    -11.8M

  • Diluted EPS (ttm)

    -0.21

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    862.98M

  • Total Debt/Equity (mrq)

    33.09%

  • Levered Free Cash Flow (ttm)

    111.58M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: